Global ATP Assays Market Revenue Grows at a CAGR of 7.98%

Introduction

Straits Research released its highly anticipated report, “Global ATP Assays Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 3.86 billion in 2025 and is anticipated to grow to USD 7.67 billion by 2034, growing at a CAGR of 7.98% from 2026-2034.

Market Dynamics

The ATP assays market is driven by rising adoption of luminescence- and enzyme-based ATP detection tools in drug discovery programs, where researchers rely on ATP quantification to evaluate cell viability, compound activity, and metabolic shifts across high-throughput screening platforms. A restraint affecting the market is the challenge of ATP instability during sample storage and extended handling, which creates variability in test outcomes and limits broader use in settings where rapid sample preparation is difficult to maintain. An opportunity emerges from the growing development of automated ATP assay platforms that streamline workflows across distributed laboratory networks, enabling coordinated research programs, multi-center testing, and wider use of ATP-based measurements in both clinical and industrial environments.

Market Highlights

• Type: Based on Type, Luminometric ATP assays dominated the market with revenue share of 35.46%.
• Application: Based on Application, Drug Discovery and Development dominated the market in 2025 with a revenue share of 34.56%.
• End User: Based on End User, Pharmaceutical and Biotechnology Companies dominated the market in 2025 with 41.23% market share.
• Regional Insights: North America held a dominant share of the global market, accounting for 40.13% share in 2025.

Competitive Players

1. BioVision, Inc.
2. 3M
3. Reaction Biology
4. Thermo Fisher Scientific Inc.
5. Promega Corporation
6. Merck KGaA
7. Agilent
8. Abcam Limited
9. Lonza
10. DH Life Sciences, LLC
11. Hygiena LLC
12. BioThema
13. Biotium 
14. AAT Bioquest, Inc
15. Abnova Corporation
16. Cell Signaling Technology, Inc.
17. Others

Recent Developments

March 2025: Biotium announced the launch of its Steady-ATP HTS Viability Assay Kit, a luminescent assay designed for high-throughput screening (HTS) applications. The assay offered exceptional sensitivity, detecting as few as 16 cells per well in a 384-well plate, and provided a stable luminescent signal with a half-life exceeding 5 hours. Its single-step, homogeneous assay format simplified workflows, making it particularly suitable for automated HTS platforms. By delivering performance comparable to existing assays, such as CellTiter-Glo at a more affordable price point, the Steady-ATP HTS Viability Assay Kit was positioned to accelerate growth in the ATP assays industry by enhancing accessibility and efficiency in cell viability assessments across pharmaceutical, biotechnology, and academic research settings.

Segmentation

1. By Type (2026-2034)
   1. Luminometric ATP Assays
   2. Enzymatic ATP Assays
   3. Bioluminescence Resonance Energy Transfer (BRET) ATP Assays
   4. Cell-based ATP Assays
   5. Others
2. By Application (2026-2034)
   1. Clinical Diagnostics
   2. Drug Discovery and Development
   3. Others
3. By End User (2026-2034)
   1. Pharmaceutical and Biotechnology Companies
   2. Clinical Diagnostics Laboratories
   3. Others